Is PT-141 (Bremelanotide) Legal in Massachusetts?

What Is PT-141 (Bremelanotide) and Why Does It Matter?

PT-141 is the research peptide name for bremelanotide, a synthetic melanocortin receptor agonist. Unlike PDE5 inhibitors such as sildenafil, bremelanotide works centrally in the brain rather than on genital vasculature. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). [1]

Mechanism of Action

Bremelanotide activates melanocortin receptors MC3R and MC4R in the central nervous system, increasing sexual desire at the neurological level. [2] This distinguishes it from every other FDA-approved treatment in the sexual dysfunction category. The subcutaneous dose is 1.75 mg, injected roughly 45 minutes before anticipated sexual activity.

How the RECONNECT Trials Established Efficacy

The RECONNECT program consisted of two replicate double-blind, placebo-controlled Phase 3 trials. Combined enrollment reached 1,247 premenopausal women with HSDD. [3] Both studies used the Female Sexual Function Index-desire domain (FSFI-d) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 as co-primary endpoints.

Bremelanotide produced statistically significant improvements on both co-primary endpoints versus placebo (P<0.001 in both trials). [3] Nausea occurred in approximately 40% of treated women, which remains the most commonly cited reason for discontinuation in clinical practice.

Federal Legal Framework: FDA Approval and Scheduling

Understanding the federal layer is the starting point before examining what Massachusetts adds or restricts.

FDA-Approved Status

The FDA granted approval to AMAG Pharmaceuticals (now Palatin Technologies / Cosette Pharmaceuticals) for Vyleesi on June 21, 2019. [1] The prescribing information is publicly available on FDA's labeling database and specifies a single-use, 1.75 mg/0.3 mL auto-injector for subcutaneous use. [4]

As an FDA-approved drug, bremelanotide is regulated under the Federal Food, Drug, and Cosmetic Act. It is not listed under the federal Controlled Substances Act schedules maintained by the DEA. [5] That means no DEA registration is required for a physician to prescribe it, and no federal quota limits dispensing.

Compounding Restrictions After 2023 to 2024 FDA Guidance

This is where the legal picture becomes more complicated for patients who have been obtaining compounded PT-141 injections from specialty pharmacies.

The FDA's Pharmacy Compounding Advisory Committee and subsequent agency guidance placed bremelanotide on the list of drug products that present "demonstrable difficulties for compounding" under Section 503A of the Federal Food, Drug, and Cosmetic Act. [6] A parallel restriction applies to 503B outsourcing facilities. [7]

The practical effect: a 503A compounding pharmacy (the category that fills individualized prescriptions) may not compound bremelanotide unless a specific patient has a documented allergy or intolerance to an ingredient in the FDA-approved Vyleesi formulation, or another clinically significant difference justifies compounding. General convenience or cost alone does not meet the legal threshold. [6]

Patients and providers should review the current FDA bulks and difficult-to-compound lists directly before assuming any compounded bremelanotide product is legally dispensed. [7]

Massachusetts State Legal Framework

Massachusetts does not add a separate controlled-substance schedule for bremelanotide. The state's controlled substance schedule is defined under Massachusetts General Laws Chapter 94C and mirrors federal DEA scheduling with some state-specific additions. [8] Bremelanotide appears on neither the federal nor the Massachusetts state schedule.

Massachusetts Board of Registration in Pharmacy

The Massachusetts Board of Registration in Pharmacy licenses and oversees all pharmacies operating in the state, including compounding pharmacies registered under 503A. [9] Because the FDA has restricted routine compounding of bremelanotide, a Massachusetts compounding pharmacy that continues to produce and dispense it without documented medical necessity justification operates outside federal compliance requirements, which in turn exposes the pharmacy to Board action.

Massachusetts Medical Practice Act and Prescribing Authority

Under the Massachusetts Medical Practice Act and the Board of Registration in Medicine's regulations, any Massachusetts-licensed physician (MD or DO), nurse practitioner (NP) with prescriptive authority, or physician assistant (PA) under a supervising physician may prescribe an FDA-approved drug for its labeled indication. [10] Prescribing Vyleesi (bremelanotide 1.75 mg) for HSDD in premenopausal women is straightforwardly within scope for any of these providers.

Off-label prescribing, including use in men, is legal in Massachusetts as it is in all U.S. States, provided the clinician documents clinical rationale. The American Academy of Family Physicians' position on off-label prescribing notes that it is both legal and sometimes the standard of care, but it requires informed consent. [11]

Telehealth Prescribing in Massachusetts

Massachusetts expanded telehealth coverage substantially during and after the COVID-19 public health emergency. The current statutory framework, codified in Massachusetts General Laws Chapter 111, Section 24L, requires that telehealth services meet the same standard of care as in-person services. [12] A provider may prescribe Vyleesi after a telehealth evaluation if:

• A valid patient-provider relationship has been established.
• The provider conducts a clinically appropriate history, including sexual health and psychosocial assessment.
• The prescribing meets the labeled indication (or off-label with documented rationale).

Prescribing a controlled substance via telehealth in Massachusetts still requires a DEA special registration under the Ryan Haight Act framework, but bremelanotide is not a controlled substance, so that restriction does not apply here.

Who Qualifies for a Bremelanotide Prescription in Massachusetts?

The FDA label defines the approved population as premenopausal women with acquired, generalized HSDD not caused by a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. [4]

Diagnostic Criteria Clinicians Use

Clinicians typically apply DSM-5 criteria for Female Sexual Interest/Arousal Disorder alongside the FSDS-DAO questionnaire to document diagnosis. [13] The North American Menopause Society (NAMS) published a 2022 position statement noting that pharmacologic treatment, including bremelanotide, is appropriate when psychological and relationship factors have been evaluated and do not fully account for the symptom burden. [14]

As the NAMS 2022 position statement states directly: "Bremelanotide (Vyleesi) is FDA approved for the treatment of acquired, generalized HSDD in premenopausal women and is an on-demand pharmacologic option that acts centrally." [14]

Contraindications That Disqualify Patients

Bremelanotide is contraindicated in patients with cardiovascular disease, specifically those with high cardiovascular risk, because it transiently increases blood pressure and decreases heart rate. [4] The FDA label reports mean maximum increases of approximately 6 mmHg systolic and 3 mmHg diastolic after a 1.75 mg dose, typically resolving within 12 hours. [4] Massachusetts providers conducting telehealth evaluations should obtain blood pressure history and, where clinically indicated, require recent in-office vitals before prescribing.

How to Get Bremelanotide Legally in Massachusetts

The clearest legal pathway in Massachusetts follows this sequence:

Step 1: Confirm Diagnosis Through a Licensed Provider

A Massachusetts-licensed MD, DO, NP, or PA evaluates the patient. The evaluation should screen for reversible causes of low desire (relationship factors, antidepressant-induced sexual dysfunction, hormonal deficiencies such as low testosterone or estrogen-related changes at perimenopause). [15] The FDA Center for Drug Evaluation and Research guidance on HSDD assessment emphasizes ruling out medication causes before initiating bremelanotide. [1]

Step 2: Obtain a Prescription for FDA-Approved Vyleesi

Given the current compounding restrictions, the provider should prescribe the brand-name product Vyleesi. The prescription is filled at any retail or specialty pharmacy licensed in Massachusetts. The drug's NDDC code and dispensing instructions are in the FDA label. [4]

Step 3: Understand Insurance Coverage and Cost

Vyleesi is covered under some commercial insurance plans in Massachusetts, though prior authorization is common. The Institute for Clinical and Economic Review (ICER) assessed both flibanserin and bremelanotide for HSDD and noted that payers frequently apply restrictive utilization management. [16] Patients who cannot obtain insurance coverage may use manufacturer copay programs or specialty pharmacy discount pathways.

Step 4: Telehealth as a Starting Point

For patients without an established sexual health provider, Massachusetts telehealth platforms that employ licensed in-state providers offer an evaluation pathway. After the telehealth visit, the electronic prescription goes to a Massachusetts-licensed pharmacy. This is a fully legal pathway under current state telehealth law. [12]

What About "Research Chemical" or Gray-Market PT-141?

Some websites sell peptide vials labeled "PT-141 for research use only" and ship to Massachusetts addresses. This is the gray area that patients and providers must understand clearly.

Selling a substance labeled "not for human use" while knowing buyers intend human use violates the Federal Food, Drug, and Cosmetic Act's adulteration and misbranding provisions. [17] The FDA has sent warning letters to peptide suppliers for exactly this conduct. [17] Purchasing such products for personal injection does not carry criminal penalties in most circumstances for the individual buyer, but the products lack pharmaceutical-grade quality controls, verified dosing, or sterility testing. A 2020 analysis of compounded and gray-market peptide products found significant variability in peptide content across commercially sourced vials, with some samples containing less than 70% of labeled active ingredient. [18]

Massachusetts state law does not create a separate legal carve-out permitting gray-market peptide purchases. The state Attorney General's consumer protection authority under Massachusetts General Laws Chapter 93A could reach deceptive sales practices in this market, but enforcement has focused on other sectors to date.

The bottom line: gray-market PT-141 purchased online is not a legal access pathway in Massachusetts. It bypasses FDA quality standards and exposes patients to unknown safety risks.

Comparing Bremelanotide to Other HSDD Treatments Available in Massachusetts

Massachusetts providers have two FDA-approved pharmacologic options for HSDD in premenopausal women.

Flibanserin (Addyi) vs. Bremelanotide (Vyleesi)

Flibanserin (Addyi) received FDA approval in 2015. It is taken daily (100 mg orally at bedtime) and carries a black-box warning for hypotension and syncope when combined with alcohol or certain CYP3A4 inhibitors. [19] Bremelanotide is taken on demand, has no alcohol interaction of comparable severity, but does carry the blood pressure elevation caution noted above.

A 2020 systematic review comparing the two agents found that neither produced large effect sizes in clinical trials; both showed modest but statistically significant benefits on desire-domain scores compared with placebo. [20] Clinician and patient preference often determines which agent to try first, with on-demand dosing a frequent reason patients prefer bremelanotide.

Testosterone Off-Label for HSDD

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women recommends considering testosterone for postmenopausal women with HSDD, but explicitly notes insufficient evidence to recommend it in premenopausal women. [21] This creates a clinical gap where bremelanotide may be the preferred on-label option for premenopausal patients.

As the Endocrine Society guideline states: "We recommend against the generalized use of testosterone by women because the indications are inadequate, and the long-term safety has not been established." [21] That caution applies specifically to broad use, while the guideline does support postmenopausal HSDD as an exception.

Documenting a Medically Necessary Prescription

Massachusetts providers documenting a bremelanotide prescription for HSDD should include the following in the medical record to meet standard-of-care expectations and support insurance authorization:

• DSM-5 or ICD-10-CM code for HSDD (F52.0 for hypoactive sexual desire dysfunction).
• FSDS-DAO or FSFI baseline score. [13]
• Documentation that reversible causes have been assessed and addressed or ruled out.
• Blood pressure reading within a clinically reasonable timeframe.
• Informed consent discussion covering nausea risk, blood pressure effects, and the requirement to avoid use in high cardiovascular risk patients.
• For off-label male use: additional documentation of clinical rationale, patient-specific risk-benefit discussion, and acknowledgment that long-term safety data in men are limited. [22]

Regulatory Timeline: How We Got Here

Understanding the regulatory history clarifies why the legal framework looks the way it does today.

The peptide was originally developed by Palatin Technologies from the melanocyte-stimulating hormone analog PT-141 in early 2000s research programs. [2] AMAG Pharmaceuticals licensed and advanced it through the RECONNECT trials. The FDA's first complete response letter in 2017 requested additional cardiovascular data before approval. [1] After satisfactory submission, approval arrived June 2019.

The subsequent tightening of compounding rules between 2022 and 2024 reflected the FDA's general posture toward compounding of drugs that have an approved commercial alternative. The agency's rationale, published in guidance documents, centers on patient safety: approved drugs carry manufacturing quality assurances that compounded versions do not. [6]

Practical Considerations for Massachusetts Patients

Massachusetts residents have several reliable options for legal access. Any primary care physician, gynecologist, or sexual medicine specialist can prescribe Vyleesi after an appropriate evaluation. Academic medical centers in Boston, including those affiliated with Harvard Medical School and Boston University, have sexual health and vulvodynia programs that commonly evaluate patients for HSDD. Telehealth platforms with Massachusetts-licensed providers offer a faster first-appointment option.

Patients should ask their pharmacy to confirm the product dispensed is the FDA-approved Vyleesi formulation, not a compounded alternative, given the restrictions described above. If a pharmacy offers a compounded version at lower cost, the patient should ask the provider whether documented medical necessity for compounding has been established in the record. [6]

A starting dose is always 1.75 mg per the FDA label. The label states the drug should not be used more than once in a 24-hour period. [4] Dose adjustment is not supported by current labeling; if 1.75 mg is not tolerated due to nausea, antiemetic pretreatment or dose timing adjustments (injecting closer to 90 minutes before activity rather than 45) may be discussed with the prescribing provider.